Physician profile
Peter Rubin
NPI 1912950411
$8,349.79
in general payments reported to CMS, 2019-2025
49 companies · $1,622 in 2025
The $1,622 reported for 2025 was more than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,693 · 2020: $985 · 2021: $1,043 · 2022: $1,132 · 2023: $557 · 2024: $1,317 · 2025: $1,622.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,255 · Education: $241.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,255.39 |
| Education | $241.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $890.04 | 2019-2023 | Reblozyl, Opdualag |
| Astellas Pharma US INC | $823.78 | 2019-2025 | Padcev, Xtandi, Vyloy |
| E.R. Squibb & Sons, L.L.C. | $739.27 | 2019-2025 | Opdivo, Reblozyl, Opdualag |
| Pfizer INC. | $525.08 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $521.43 | 2019-2025 | Calquence, Lynparza, Enhertu |
| Glaxosmithkline, LLC. | $359.17 | 2021-2025 | Ojjaara, Jemperli, Zejula |
| Abbvie INC. | $323.25 | 2021-2025 | Epkinly |
| Puma Biotechnology, INC. | $295.11 | 2019-2022 | |
| Pharmacyclics LLC, An Abbvie Company | $288.85 | 2019-2023 | Imbruvica |
| Janssen Biotech, INC. | $285.52 | 2019-2025 | Erleada, Rybrevant, Talvey |
| Takeda Pharmaceuticals U.S.A., INC. | $277.49 | 2019-2025 | Alunbrig, Ninlaro, Fruzaqla |
| Amgen INC. | $271.01 | 2019-2025 | Lumakras, Imdelltra (Amg757) |
| Genmab U.S., INC. | $226.18 | 2024-2025 | Epkinly |
| Merck Sharp & Dohme LLC | $225.01 | 2020-2025 | Keytruda |
| Epizyme, INC. | $214.55 | 2021-2022 |
Show all 48 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Rubin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.